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Abstract
Background: Lifestyle factors and pharmacological compounds activate genetic mechanisms that influence the 
development of atherosclerotic and other diseases. This article reviews studies on natural and pharmacological gene 
activation that promotes health and enhances longevity.
Results: Living habits including healthy diet and regular physical activity, and pharmacotherapy, upregulate genes 
encoding enzymes and apolipoprotein and ATP-binding cassette transporters, acting in metabolic processes that 
promote health and increase survival. Cytochrome P450-enzymes, physiological factors in maintaining cholesterol 
homeostasis, generate oxysterols for the elimination of surplus cholesterol. Hepatic CTP:phosphocholine 
cytidylyltransferase-α is an important regulator of plasma HDL-C level. Gene-activators produce plasma lipoprotein 
profile, high HDL-C, HDL2-C and HDL-C/cholesterol ratio, which is typical of low risk of atherosclerotic disease, and also 
of exceptional longevity together with reduced prevalence of cardiovascular, metabolic and other diseases. High HDL 
contributes to protection against inflammation, oxidation and thrombosis, and associates with good cognitive 
function in very old people. Avoiding unhealthy stress and managing it properly promotes health and increases life 
expectancy.
Conclusions: Healthy living habits and gene-activating xenobiotics upregulate mechanisms that produce lipoprotein 
pattern typical of very old people and enhance longevity. Lipoprotein metabolism and large HDL2 associate with the 
process of living a very long life. Major future goals for health promotion are the improving of commitment to both 
wise lifestyle choices and drug therapy, and further the developing of new and more effective and well tolerated drugs 
and treatments.
Introduction
It is common knowledge that diet, exercise and less stress
are likely to enhance longevity, but the mechanisms are
not well known. Chronic stress can lead to behavioral and
somatic disorders such as anxiety, depression, obesity,
dyslipidemia, metabolic syndrome, and atherosclerosis
with its cardiovascular sequalae, premature cardiovascu-
lar disease and death [1]. On the other hand, prudent diet
and regular physical activity, and pharmacological com-
pounds, have metabolic effects that reduce the risk of car-
diovascular and other diseases. Atherosclerotic
cardiovascular disease is the leading global health prob-
lem as assessed by mortality [2], and the research focus-
ing on the atherosclerotic vascular process is of particular
importance for health promotion.
Population studies performed in the 1970s identified
high plasma apolipoprotein AI (apo AI) and HDL choles-
terol (HDL-C) levels as powerful indicators of a low risk
of coronary heart disease (CHD) and cerebrovascular dis-
ease [3,4], whereas high apo B and LDL-C indicate an
increased risk of CHD and death. The close relation of
the major risk factors to cardiovascular diseases led to
great continuing interest in agents with potential to raise
apo AI and HDL-C and reduce apo B and LDL-C. Clinical
studies soon revealed that drugs which induce protein
synthesis increase hepatic cytochrome P450 activity and
plasma apo A1 and HDL-C and the HDL-C/cholesterol
ratio [5,6]. The inducing agents are gene-activators that
can also upregulate hepatic LDL receptor (LDLR) gene
and reduce plasma LDL-C [6,7]. These compounds influ-
ence cholesterol homeostasis also in other tissues includ-
ing vasculature, intestine and the brain. A number of
physiological and pharmacological compounds act, via
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against the atherosclerotic process, whereas mutations in
the genes can promote atherogenesis. The ability to con-
trol the expression of these genes provides a possibility to
influence the development of cardiovascular disease and
to extend lifespan. Investigations performed in the last
few years focusing on this possibility have resulted in sig-
nificant positive results. This article reviews studies on
natural and pharmacological gene activation that
regresses atherosclerosis, reduces the incidence of car-
diovascular and other diseases, and enhances longevity.
Liver and plasma lipids and proteins and gene-
activation
Both endogenous and exogenous factors act on the risk
and the development of atherosclerosis. An endogenous
induction of apo AI synthesis resulting in high plasma
apo AI and HDL-C concentration has been identified as a
cause of familial hyperalphalipoproteinemia which is
characterized by a low death rate from CHD and pro-
longed life expectancy [8], while a low apo AI synthesis
rate leads to hypoalphalipoproteinemia [9] that promotes
atherogenesis. Similarly, drugs which induce hepatic pro-
tein and phospholipid synthesis and P450 activity, could
increase plasma apo AI and HDL-C [10] (Figure 1) and
the HDL-C/cholesterol ratio [11] that reflects an
enhanced hepatic secretion of apo AI-phospholipid com-
plexes. Corresponding to these effects, an overexpression
of human apo AI transgene prevents atherogenesis [12]
and an infusion of apo AI-phospholipid complexes in
humans regresses atherosclerosis [13]. The liver produces
the majority of HDL phospholipids, phosphatidylcholine
(PC) being the primary phospholipid in cellular mem-
branes and plasma lipoproteins [14]. Hepatic CTP: phos-
phocholine cytidylyltransferase-α (CCTα) is the key
enzyme in the synthesis of PC and an important regulator
of plasma HDL-C level (next chapter).
Enzymes, atheroprotection and atherosclerosis
A number of enzymes participate in processes that pro-
tect arteries from atherosclerosis, including P450-
enzymes belonging to different cytochrome (CYP)
classes, CCTα, sirtuin 1(SIRT1) and paraoxonase-1
(PON1).
P450-enzymes have in addition to recognized pharma-
cological and toxicological functions, important physio-
logical functions in the control of cellular homeostasis.
P450-isoenzymes such as CYP7A1, CYP27A1 and
CYP46A1 are natural regulators of cholesterol homeosta-
sis which hydroxylate it to oxysterols (OHCs) [15,16].
CYP7A1 is essential for the conversion of cholesterol to
7α-OHC and as the key rate-limiting enzyme in the syn-
thesis of bile acids. A mutation in CYP7A1gene can
reduce bile acid synthesis, increase hepatic cholesterol,
and present as a phenotype reminiscent of that in familial
hypercholesterolemia (FHC) associated with premature
atherosclerotic disease [17]. Correspondingly, a low rate
of bile acid synthesis in FHC predicts enhanced mortality
from CHD [18], and bile acid binding and CYP7A1
inducing resin therapy reduces cardiovascular mortality
[19]. Side-chain OHCs such as 27OHC, 24SOHC and
25OHC generated by CYP27A1, CYP46A1 and choles-
terol 25-hydroxylase, respectively, are signal mediators
that have been identified as activators of liver X receptors
(LXRs) both in vitro and vivo [20-22]. The OHCs influ-
ence cellular cholesterol homeostasis by serving as
ligands for LXRs that upregulate genes acting in choles-
terol elimination pathways, and through the suppression
of SREBP (sterol regulatory element binding protein)
maturation and promoting the degradation of hydroxym-
ethylglutaryl CoA reductase (HMGCOAR), the rate-lim-
iting enzyme of cholesterol synthesis [23]. CYP46A1
influences cholesterol homeostasis in the brain by con-
verting it to 24SOHC, which readily passes the blood
brain barrier and may also as a ligand for LXR promote
the efflux of cholesterol. CYP3A4, a key enzyme in the
metabolism of xenobiotics also affects the fate of choles-
terol. CYP51A1 is the only P450 enzyme participating in
cholesterol synthesis. The synthesis generates metabo-
lites including, 24S,25 epoxycholesterol which suppresses
SREBP-2 process and HMGCOAR activity, and may as a
ligand for LXR prevent cholesterol accumulation [24].
Cardiovascular P450s include enzymes belonging to
several CYP families [25-27]. Many of them generate
eicosanoids that have important functions in vascular
physiology. The CYP2C and 2J epoxygenases metabolize
arachidonic acid to eicosanoids, epoxyeicosatrienoic
acids (EETs) which are mediators in vascular signaling
processes. CYP4 ω-hydroxylases convert EETs to dihy-
droxyeicosatrienoic acids (DHETs). Both EETs and
DHETs activate peroxisome proliferator-activated recep-
tors (PPARs), which have a role in vascular functions [26].
EETs are vasodilating compounds which inhibit inflam-
matory response, promote fibrinolysis and may function
as endogenous antiatherogenic compounds [25,27]. A
mutation in CYP2J2 gene has been linked to reduced
plasma EET concentrations and increased risk of CHD
[27]. CYP4A and CYP4F enzymes convert arachidonic
acid to 20-hydroxy - eicosatetraenoic acid (20HETE) [26].
Vascular ω-hydroxylases further metabolize 20HETE to
20-carboxy-arachidonic acids which also activate PPARα
and PPARγ receptors [27]. Several drugs including statins
and fibrates are PPAR activators [25,28].
CCTα, the rate-limiting enzyme in the synthesis of PC,
has been identified as a key player in maintaining plasma
HDL-C levels [14]. CCTα knock-out mice show reduced
hepatic PC content as well as ABCA1 (ATP-binding cas-
sette A1) expression in hepatocytes and marked decrease
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impaired by CCTα deficiency in the hepatocytes [14].
Adenoviral delivery of CCTα to knock-out mice restored
PC mass in knock-out livers, increased hepatic ABCA1
levels, and normalized HDL-C levels in vivo [14]. CCTα
is also necessary for protection against cholesterol-
induced cell death [14]. An elevation of cellular choles-
terol induces the generation of side-chain OHCs that
upregulate CCTα and PC synthesis [29]. Relatively low
concentrations of OHCs increase CCTα activity and PC
synthesis in adose-dependent manner.The OHCs could
directly act on CCTα and increase PC synthesis, and
thereby act against cholesterol toxicity [29]. The study of
Gehrig et al. showed that direct activation of CCTα by
OHCs is a potential mechanism to maintain sterol/phos-
pholipid content of membranes within normal boundar-
ies [29].
SIRT1 is a nicotinamide adenine dinucleotide-depen-
dent deacetylase that regulates physiological processes
including systemic and hepatic glucose, lipid and choles-
terol homeostasis [30,31]. SIRT1 has broad biological
functions in growth regulation, stress response, tumori-
genesis, endocrine signaling, and extended lifespan [32].
The enzyme is connected to important metabolic
changes and regulatory proteins in response to caloric
restriction. Fasting increases SIRT1 activity that reduces
insulin secretion and increases insulin sensitivity, stress
resistance and cell survival [32]. Hepatic SIRT1 controls
the expression of genes involved in cholesterol metabolic
pathways [30]. It upregulates, via LXR activation, ABCA1
transporter and cellular cholesterol efflux to apo AI and
HDL formation [31]. The expression of ABCA1 is
reduced in SIRT1 knockout mice, resulting in defective
cholesterol efflux and lower HDL-C levels, and blunted
response to LXR agonists [31]. SIRT1, which extends life
span in several species including mammals has emerged
as a drug development target for treating age-dependent
diseases [31-33].
PON1, an enzyme with antioxidant function primarily
synthesized in the liver, is associated with HDL in the
subintimal space of the artery. HDL together with PON1
is ideally positioned to protect LDL from oxidative modi-
Figure 1 Relation of plasma HDL-C and apolipoprotein AI to liver cytochrome P450, phospholipid (PL) and protein in man. Some patients 
were treated with gene-activating drugs (Luoma PV el al, Lancet. 1982, 1:625).
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that initiate atherogenesis. Lifestyle factors, a number of
diseases, drugs and nonpharmacologic factors may influ-
ence PONI 1 activity (reviewed in ref. 34). An atherogenic
diet and smoking decrease PON1 activity, and it is low in
patients with surgical menopause, type 1 diabetics with
elevated blood glucose, chronic hepatitis and cirrhosis,
rheumatoid arthritis and Alzheimer's disease. On the
other hand, exercise, moderate alcohol consumption,
hormone replacement therapy, and the use of statins,
fibrates or aspirin associates with increased PON1 activ-
ity [34]. Patients with a mutated PON1 gene show accel-
erated atherosclerosis as assessed by carotid intima-
media thickness (IMT) [35], and two prospective studies
associated low PON1 activity with high incidence of
major cardiovascular events [34]. An overexpression of
human PON1 in mouse models of atherosclerosis
decreased aortic lesion size [34].
Receptors, transcription factors, and risk factors
Nuclear receptors regulate the expression of genes
encoding enzymes, transporters and other proteins
involved in metabolic homeostasis [36]. LXR receptors
(LXRα and LXRβ) function as cholesterol sensors and
mediators that act on genes involved in the absorption,
efflux, and transport of cholesterol to the liver, bile acid
synthesis, biliary sterol secretion, and the synthesis of
nascent HDL [37]. LXR activation downregulates intesti-
nal Niemann-Pick C1 like transporter which is critical for
cholesterol absorption [38], and has similar effect on
CYP51A1 and squalene synthase, key enzymes in the syn-
thesis of cholesterol [39]. PPAR receptors, PPARα, PPARγ
and PPARδ, control lipid and glucose metabolism, as well
as depress the inflammatory response in various tissues
and cells including macrophages and monocytes [36,40].
PXR is a regulator of xenobiotic metabolizing P450
enzymes which hydroxylate cholesterol and its metabo-
lites [41]. PXR also is a positive regulator of CYP27A1 in
human intestinal cells and could via LXRα activation
stimulate cholesterol efflux from intestinal cells to apo AI
and HDL formation [42].
SREBPs are transcription factors that activategenes
dedicated to the synthesis and uptake of cholesterol, fatty
acids, phospholipids and triglycerides [7]. SREBP-2 pref-
erentially activates genes involved in the synthesis of cho-
lesterol. LDLR is a membrane cholesterol transporter that
mediates cellular uptake of LDL-C. A depletion of hepatic
cholesterol activates SREBP processing that induces the
expression of LDLR. Scavenger receptor B1 (SR-B1) is a
cell-surface HDL receptor expressed in several tissues
including the liver [43]. It facilitates cholesterol efflux
from peripheral cells to HDL and mediates the hepatic
uptake and biliary secretion of cholesterol. Studies using
SR-B1- transgenic and - deficient mouse models have
established the antiatherogenic activity of SR-B1 in vivo.
ABC-transporters, apolipoproteins, HDL and 
cholesterol
ABC transporters have a major role in the control of
whole-body cholesterol homeostasis [44]. ABCA1 regu-
lates the rate-limiting step in the biogenesis of HDL parti-
cles by mediating the efflux of cholesterol and
phospholipids across cellular membranes [44-46].
Hepatic ABCA1 is the main factor in the generation of
HDL-C levels in the circulation. ABCG1 which is
expressed in several tissues facilitates cholesterol efflux to
HDL. ABCG4 transporter acts on cholesterol in the
brain, and ABCG5 and ABCG8 in the liver and intestine.
ABCA7 may mediate HDL assembly and generate choles-
terol-poor HDL [47]. Apo AI, the predominant protein
constituent of HDL, is produced by liver and intestine. It
removes cellular cholesterol and phospholipids trans-
ported to plasma membrane [44]. Lipid-free and lipid-
poor apo AI are the key molecules in the initiation of
HDL formation. Apo AI is an activator of lecithin: choles-
terol acyltransferse (LCAT) and a ligand for the binding
of HDL to SRB1. Other apolipoproteins including AII, E,
CI, CII, CIII, and AIV also serve in ABCA1-mediated
cholesterol efflux [44].
Genes, familiality, risk factors and lifespan
The contribution of genetic factors to life expectancy has
become increasingly important at advanced ages [48].
Exceptional longevity is also familial. People in the most
advanced decades of life, especially centenarians, possess
lipoprotein profile that is typical of low risk of atheroscle-
rotic disease. They have high HDL-C and HDL2-C [49],
and also high HDL-C/cholesterol ratio [49,50] and low
cholesterol and LDL-C as compared to septuagenarians
[50,51]. Large HDL, i.e. the subclass HDL2, and large LDL
have been identified as typical lipoproteins of exceptional
longevity [52]. The predominance of large lipid-rich
HDL2 subclass is the most reproducible phenotype
among very old people [49], who also have reduced prev-
alence of cardiovascular diseases, hypertension, meta-
bolic syndrome and diabetes mellitus [48,49,52]. The
offsprings of very old people also have lower prevalence
of cardiovascular disease and cardiovascular risk factors
and a greater survival rate when compared to the controls
who had one parent die at average life expectancy [53,54].
Diet - gene activation, risk factors, and health 
effects
Dietary factors have significant metabolic and health
effects. Diet constituents such as soy proteins and alcohol
induce the expression of apo AI gene and raise HDL-C,
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effect [55]. Vitamin B3 or niacin has recently been shown
to increase apo AI production in man [56] and vitamin A
deritative 9-cis retinoid acid to upregulate apo AI gene
expression in HepG2 cells [55,57]. Weight control by a
low calorie diet with adequate nutrition has positive
effects. It increases insulin sensitivity, stress resistance,
and cardioprotection, and decreases insulin secretion, fat
storage and glycolysis [32]. The activating effect of the
diet on SIRT1 could contribute to atheroprotection. The
enzyme is positive regulator of LXR and cholesterol
efflux via HDL formation. SIRT1 overexpression in fasted
state could also induce hepatic CYP7A1 and decrease
hepatic cholesterol content [30,33] that upegulates LDLR
pathway and reduces plasma LDL-C.
Natural mechanisms protect cells from harmful effects
of the diet. An atherogenic cholesterol-rich diet upregu-
lates hepatic P450-enzymes that reduce cholesterol toxic-
ity by inducing its catabolism to OHCs and elimination
[58], and an activation of hepatic LXRα to protects ani-
mals from atherosclerosis of dietary origin [59]. Fatty
acids and eicosanoids are endogenous activators of
PPARs that also respond to high fat diet and act against
atherogenic dyslipidemia and promote reverse choles-
terol transport [36]. PXR mediates the activation of
hepatic cholesterol metabolizing P450-enzymes and
thereby protects against acute toxicity caused by a high-
cholesterol diet [41].
Randomized trials show that modest consumption of
oily fish, 1 to 2 servings per week, reduces CHD mortality
by more than one third, with 17% reduction in total mor-
tality, and indicate consistent and substantial reductions
in cardiovascular risk related to lower trans fat consump-
tion, consumption of whole grains, legumes, and cereal
fiber, and consumption of fruits and vegetables [60].
Great improvements can be reached by promoting Medi-
terranian-type of diet [61] which is characterized by high
intake of olive oil, vegetables, legumes, fruits nuts and
cereals, a moderately high intake of fish, but low intake of
saturated lipids, meat and poultry, and a regular but mod-
erate intake of ethanol, primarily in the form of wine and
generally during meals [62]. The people on Mediterra-
nian diet have a favorable cardiovascular risk factor pro-
file, low systolic and diastolic blood pressure, and fasting
blood glucose and insulin levels [63], together with low
mortality rate from CHD, cardiovascular disease, cancer,
and also all-cause mortality [62-64].
Physical activity - metabolic and health effects
Regular physical activity has multiple metabolic and
health effects (Table 1) [60]. It reduces plasma LDL-C,
cholesterol and triglycerides, and raises HDL-C and
HDL2-C [65]. It also upregulates LXRα, PPARγ, and scav-
enger receptor CD36 (cluster of differentiation 36) that
leads to an increased uptake of atherogenic oxidized LDL,
and ABCA1 and ABCG1 in leucocytes [66]. Endurance-
trained men show high VO2max (peak pulmonary oxygen
uptake) together with high HDL-C, apo AI, and increased
plasma LCAT activity and cholesterol efflux from mac-
rophages compared with normally active men [67,68].
The increased LCAT activity leads to an increased pro-
duction of HDL2 [69]. Experimental studies also show
that endurance exercise upregulates hepatic P450, LDLR
and SR-B1, increases the catabolism of cholesterol to bile
acids, and prevents gallstone formation [70]. In addition,
regular physical activity helps maintaining weight con-
trol, improves glucose - insulin homeostasis, lowers
blood pressure, and improves psychological wellbeing
[60]. It also reduces, in proportion to overall physical
activity, the mortality form CHD, cardiovascular disease,
and cancer, and also from any cause [71,72]. Regular
physical exercise also facilitates smoking cessation that
reduces total mortality by approximately one third [60].
Stress - mediators and diseases
The main central molecular mediators of the stress sys-
tem are corticotropin-releasing hormone, arginine vaso-
pressin and norepinephrine, and key peripheral
mediators are corticotropin, cortisol, arginine vasopres-
sin, norepinephrine, epinephrine and interleukin-6 [1].
The stress system is activated in a coordinated fashion
during acute stress influencing central and peripheral
functions that are important for adaptation and survival.
Chronic activation of stress system is associated with
many negative manifestations. It can lead to common
Table 1: Effects of regular aerobic physical activity1
Upregulation
Receptors LXRα, PPARγ SR-B1, LDLR, CD36
Enzymes CYPs, LCAT, PON1
Transporters ABCA1, ABCG1, Apo AI
Change in risk factor
Increase Apo AI, HDL-C, HDL2-C
Decrease LDL-C, cholesterol, triglycerides
Improvement cellular cholesterol efflux
peak pulmonary oxygen uptake
glucose - insulin homeostasis
weight control
psychological wellbeing
Lowering blood pressure
Decrease CHD, cardiovascular, cancer and 
total mortality
1 The list of abbreviations precedes the reference list.
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and development of obesity and metabolic syndrome
with insulin resistance, dyslipidemia, arterial hyperten-
sion, type 2 diabetes, and atherosclerosis ultimately
resulting in premature cardiovascular disease and death
[1].
Studies on model organisms and longevity
Experiments in model organisms such as Caenorhabditis
(C) elegans and Drosophila (D) melanogaster have identi-
fied a number of potential genetic mechanisms which can
increase survival. The genes involved include daf-2, an
insulin receptor-like gene, and daf-12, a nuclear receptor
gene in C. elegans, and catalase and suproxide dismutase
genes in D. melanogaster. Experiments in these organ-
isms have demonstrated that changes in genes can mark-
edly increase lifespan, but to what extent they explain
variation in humans is still uncertain [73]. The environ-
ments in which the genes come to expression in these
species and humans are markedly different, and caution
should be taken in extrapolating the relevance of results
on genetic variation in model organisms to the human
situation [73].
Xenobiotic gene-activators - antiatherogenic 
effects
A number of xenobiotics are gene-activators that have
antiatherosclerotic actions. Several of them, but not all,
are P450 inducers.The major effects of statins, niacin,
fibrates and cholestyramine, important drugs for treat-
ment of dyslipidemias, are presented here. Recent studies
have contributed significant positive results. Other com-
pounds with beneficial effects include angiotensin-con-
verting enzyme inhibitors (ACEIs), calcium channel
blockers (CCBs), angiotensin receptor blockers (ARBs),
glitazones, anticonvulsants, retinoids and alcohol [74].
Statins inhibit HMGCOAR and cholesterol synthesis
and decrease hepatic cholesterol that activates SREBP
processing and upregulation of LDLRs on the surface of
liver cells and reduces plasma LDL-C [7]. The drugs also
induce PPARα and apo AI synthesis in liver cells [58] and
raise plasma apo AI, HDL-C and the subfraction HDL2-C
[75]. Statins also stimulate CYP4 ω-hydroxylases in
human liver microsomes and CYP2 epoxygenase in
native endothelial cells which generate PPAR-activating
eicosanoids [25,28]. The drugs upregulate via PPAR acti-
vation LXR, ABCA1 and ABCG1 genes in cholesterol-
loaded macrophages and hepatocytes, and promote cho-
lesterol efflux to apo AI and HDL [58]. Statins also
induce, through SREBP-2 activation, CYP4F2 [76] and
ABCA1 [77] genes in human hepatocytes.
Niacin, which is not a P450-inducer, has recently been
shown to stimulate apo AI production in patients with
combined hyperlipidemia [56]. The drug also upregulates
PPARγ, LXRα and ABCA1 genes and promotes HDL-
dependent cholesterol efflux from monocytoid cells [78],
and raises apo AI and HDL-C, particularly HDL2-C [79],
and reduces LDL-C and triglycerides. Statin - niacin
combination is more effective than monotherapy in rais-
ing HDL-C and HDL2-C and reducing LDL-C and trig-
lycerides [80]. Fibrates, PPARα agonists which induce
P450s including ω-hydroxylases and apo AI synthesis
[58], raise plasma apo AI and HDL-C and reduce LDL-C
and triglycerides. Fibrate-caused PPARα activation
upregulates LXR, SR-B1 and ABCA1 genes and promotes
apo AI-mediated cholesterol efflux [40]. Cholestyramine
binds bile acids, induces CYP7A1 and depletes choles-
terol in hepatocytes, and increases LDL-C elimination via
the upregulated LDLR pathway, and also induces apo AI
synthesis and raises plasma apo AI and HDL2-C subfrac-
tion [81]. The combination of resin and statin is effective
in reducing circulating cholesterol levels [82].
Xenobiotic gene-activators, diseases and longevity
Several xenobiotic gene-activators prevent or regress ath-
erosclerosis and increase survival. Recent studies have
contributed significant positive results. The major effects
of statins, niacin, fibrates, cholestyramine, ARBs, ACEIs
and CCBs are presented here. Other compounds includ-
ing pioglitazone, anticonvulsants and alcohol also have
positive effects [74].
Statins including pitavastatin [83], fluvastatin [84],
pravastatin [85], rosuvastatin, atorvastatin and simvasta-
tin [58], regress coronary atherosclerosis as assessed by
intravascular ultrasonography (IVUS) technique. Statin
therapy that caused a moderate rise in HDL-C level
together with significant LDL-C lowering was particu-
larly effective in regressing atherosclerotic plaque [86].
The statins also reduce both nonfatal and fatal cardiovas-
cular events, and all-cause mortality [58]. The drugs
improved survival rate also of people with cardiovascular
risk factors but without cardiovascular disease [87], and
population studies linked statin therapy with reduced
mortality rate chronic obstructive pulmonary disease and
pneumonia [88]. A comparison of mortality of statin
users (n = 228,528) versus nonstatin users (n = 1,261,938)
in the United States veteran population revealed a highly
significant increase in survival rate [89]. Almost half of
statin users had started the therapy at the age of 70 years
or older, and the conclusion was that the therapy is an
effective strategy for promoting longevity.
Niacin added to statin therapy regressed atherosclero-
sis in carotid arteries as measured by IVUS [90], and a fol-
low-up trial revealed increased survival rate for
individuals initially randomized to niacin [58]. Fibrates
prevent the progression of coronary atherosclerosis as
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for dyslipidemia increased survival rate as compared with
dyslipidemic persons without treatment [91], and a fol-
low-up control of the Helsinki Heart study revealed that
gemfibrozil reduces CHD mortality, and also total mor-
tality of obese persons with high triglycerides [92].
Cholestyramine therapy had positive effect on coronary
atherosclerosis assessed by angiography and it reduced
the risk of CHD death and/or nonfatal myocardial infarc-
tion [93], and resin therapy, cholestyramine or colestipol,
reduced cardiovascular mortality [19].
ACEIs, ARBs and CCBs, drugs indicated for cardiovas-
cular diseases, also have antiatherosclerotic effects. ACEI
treatment has been shown to reduce carotid IMT [94]
and ARB treatment plaque volume in coronary arteries
[95], and CCB therapy to widen the lumen and inhibit the
intimal hyperplasia in coronary stent lesions [96]. The
antiatherosclerotic effects could contribute to the
improved survival rate reported for ACEI- [97] and CCB-
[98] treated subjects, and to reduced rate of cardiovascu-
lar events of ARB-treated individuals [97].
Goals for health promotion
The effects of healthy lifestyle and pharmacotherapy, the
decrease in the incidence of cardiovascular and other dis-
eases and the increase in life expectancy, emphasize the
importance of future actions that improve commitment
to both healthy living habits and drug therapy, and fur-
ther on developing of new and more effective and well
tolerated drugs and therapies. Poor dietary habits,
unhealthy composition of diet with excess calories, inade-
quate physical activity and adiposity, smoking, and excess
stress, are major problems that affect health in modern
societies. Hence, the clinical evaluation and treatment of
dietary, physical activity, and other living habits must
become as routine and familiar as assessment of blood
lipid and glucose levels, and blood pressure. It is also
important to avoid unhealthy stress and to learn to how
to manage it. Effective focusing on life style risk prevents
or delays the occurrence of CHD, cardiovascular disease,
diabetes mellitus and obesity, and reduces the need of
drug therapy or even makes it unnecessary.
The positive effects of gene activators have led to inten-
sive search for new molecules with potential effects on
risk factors and effectors in the antiatherogenic metabolic
cascade, such as enzymes, receptors and transporters.
HDL and its constituents are key therapeutic targets for
preventing atherosclerotic lesion formation and promot-
ing the regression of established atherosclerotic lesions
[99]. Many P450-inducing compounds increase apo AI,
HDL-C and the HDL-C/cholesterol ratio [5,6], and new
molecules acting on cholesterol metabolizing P450-
enzymes in the liver, brain and other tissues are also
potentially effective antiatherogenic agents. Investiga-
tional agents also include new LXR agonists and PPAR
agonists and other HDL elevators, and compounds
enhancing the expression of ABC transporters [74]. The
agonists of PXR, which affects the fate of cholesterol, also
have potential to activate antiatherogenic mechanisms.
The evaluation of the effects of the combinations lifestyle
factors and drug treatments and of drug combinations
can significantly improve therapeutic possibilities.
Discussion
The reviewed studies show that living habits and pharma-
cological compounds upregulate genetic mechanisms
that beneficially affect lipoprotein metabolism, promote
wellbeing and increase survival. The studies also associ-
ate lipoprotein metabolism and HDL2 subclass with the
process of living a very long life. The liver is the principal
site for the synthesis of lipids and proteins, and changes
in hepatic function can significantly affect lipoprotein
metabolism and the development of atherosclerotic and
other diseases.
The first studies clarifying the effects of genes on
hepatic proteins and P450 activity and plasma apolipo-
protein and lipoprotein risk factors were performed in
the 1970s. Our original observations linked gene activa-
tion and P450 induction with increase in hepatic protein
and phospholipid concentration and with cardiovascular
risk factor profile that is typical of low risk of atheroscle-
rotic disease [5,6], and that later on has been found typi-
cal also for very old people together with decreased
incidence of cardiovascular, metabolic and other diseases.
A number of gene-activators including statins, niacin,
cholestyramine, nifedipine [100], pioglitazone [101] and
phenytoin [102], and also alcohol consumption [103],
increase HDL-C and the large, PC-rich HDL2-C, and par-
ticularly statins, niacin and cholestyramine are effective
in reducing cholesterol and LDL-C. HDL2 -C also rises
with ageing and is typical for very old people [49,52].
Several gene-inducing mechanisms are active in the
prevention and regression of atherosclerosis. Both life-
style factors and pharmacological compounds upregulate
apo AI and LDLR gene expression and raise HDL-C and
and reduce LDL-C, respectively. They similarly activate
several genes in the cholesterol elimination pathways,
including nuclear receptors, ABC transporters, and
enzymes such as CYPs and CCTα. Many gene-activators
increase the subfraction HDL2 which has high apo AI and
phospholipid content compared with HDL3, and key role
in the antiatherogenic effect of HDL [104]. The individu-
als with high P450-activity in the liver, show high plasma
HDL-C, HDL2-C and HDL-C/cholesterol ratio, while a
deficient P450-activity leads to cholesterol accumulation,
hypercholesterolemia and xanthoma formation and pro-
motes atherogenesis [11,105]. The increase of HDL-C
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Page 8 of 12and HDL2-C with increasing hepatic P450 activity sug-
gests that the cholesterol metabolizing CYPs, that are
particularly prevalent in the liver [44], enhance the gener-
ation of OHCs and activation of HDL and HDL2 raising
mechanisms. The relation of plasma HDL-C (Figure 1)
[10,11] and liver P450 (Figure 2) [106] to hepatic phos-
pholipids also suggests that the enrichment of PC in
HDL2 with increasing P450 activity reflects the effect of
these CYPS on the synthesis of PC, the primary phospho-
lipid of HDL. An effective CYP-mediated OHC genera-
tion could induce hepatic CCTα and PC synthesis [29],
and consequently increase HDL-C, and particularly the
PC-rich HDL2-C. A similar effect of a P450-inducing
agent on OHC production and hepatic PC synthesis
could also have a role in the elevation of HDL-C and
HDL2-C. The studies on CCTα-deficient mice showing a
decrease of PC content in the liver, the principal source of
PC in HDL, as well as ABCA1 expression in hepatocytes
and marked lowering of HDL-C levels [14], support this
possibility. Correspondingly to these effects, a delivery of
CCTα to knock-out mice increased hepatic PC mass and
ABCA1 levels, and plasma HDL-C levels in vivo. In
agreement with these findings, the high phospholipid
content in HDL2 particles has been identified as an effi-
cient driving factor for cholesterol removal from periph-
eral cells [107,108], and HDL phospholipids correlate
inversely with the severity of angiographically defined
coronary atherosclerosis [109].
The OHCs mediate the activation of antiatherogenic
mechanisms. They upregulate, via LXR, effectors in cho-
lesterol efflux including ABCA1, ABCG1 and apo AI. An
elevation of cellular cholesterol upregulates hepatic P450-
enzymes, OHCs [110], CCTα [29], and ABCA1, and
increases plasma HDL-C [111], whereas targeted deletion
of hepatic ABCA1 markedly reduces it [112]. Corre-
sponding to this effect, a recent study of Brunham et al.
showed that mice lacking hepatic ABCA1 display a signif-
icant accumulation of cholesterol in aorta and increase in
aortic atherosclerotic lesion area, while a selective dele-
tion of macrophage ABCA1 did not significantly modu-
late atherogenesis [113]. These studies on hepatic
enzymes, mediators, lipids and transporters, and athero-
sclerosis, emphasize the key role of liver in maintaining
cholesterol homeostasis and in the prevention and
regression of atherosclerosis.
Gene-activators increasing HDL and apo AI have, in
addition to cholesterol efflux and transport, a number of
other favorable effects (Table 2) [6,114]. They inhibit
inflammatory processes in vascular cells, promote
endothelial cell nitric oxide (NO) release and vasodilata-
tion, and have a variety of antioxidative actions. HDL
together with PON1 and other enzymes inhibit the
atherogenic oxidative modification of LDL in the arterial
wall. Other antiatherogenic actions of HDL/apo AI
include inhibition of platelet aggregation, stimulation of
prostacyclin production and fibrinolysis, and inhibition
of expression adhesion molecules and apoptosis of
endothelial cells. Interestingly, high plasma HDL and apo
AI also associate with good cognitive performance in very
old people [49,115], suggesting that the antiaggregation,
anti-inflammatory and antioxidative effects HDL/apo AI
have a role in this relation.
Figure 2 Relationship between cytochrome P450 and phospho-
lipid concentrations in human liver. Δ patients with normal liver his-
tology,  patients with normal liver but undergoing inducing drug 
therapy,  patients with fatty liver,  patients with liver cirrhosis. r = 
0.909, p < 0.001 for all subjects. For fatty liver group, r = 0.834, p < 0.001 
(Savolainen MJ et al, Eur J Clin Pharmacol. 1985, 27:727-732).
Table 2: Antiathrogenic effects of HDL/apolipoprotein AI
Efflux and reverse transport of cholesterol
Anti-inflammatory
- inhibition of the expression of vascular cell 
adhesion molecules
- stimulation of endothelial NO production
Antioxidative
- inhibition of oxidative modification of LDL
Antithrombotic
- inhibition of platelet aggregation
- fibrinolysis
- increase of prostacyclin production
Facilitation of endothelial cell function and repair
Inhibition of apoptosis of endothelial cells
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The studies performed in the 1970s and thereafter have
demonstrated that living habits and pharmacological
compounds upregulate genetic mechanisms which act in
maintaining cellular homeostasis, have beneficial meta-
bolic and health effects, and enhance longevity. Major
findings of the investigations associate gene activation
and hepatic protein and phospholipid metabolism with
plasma lipoprotein profile, high HDL-C, HDL2-C and
HDL-C/cholesterol ratio, that is typical of low risk of car-
diovascular and other diseases, and also of exceptional
longevity. In addition, high HDL contributes to protec-
tion against oxidation, inflammation and thrombosis, and
associates with good cognitive function in people of
advanced age.
The studies on nuclear receptors, enzymes, phospho-
lipids, proteins and ABC transporters indicate that the
liver has a major role in atheroprotection and regression
of atherosclerosis. P450-enzymes, physiological key fac-
tors in maintaining cholesterol homeostasis generate
oxysterols for the removal of excess cholesterol. Hepatic
CCTα is the key enzyme in the synthesis of PC and an
important regulator of plasma HDL-C level, and the
increased phospholipid mass in HDL2 is an efficient driv-
ing factor for cholesterol removal from peripheral cells.
Healthy lifestyle choices counteract, via natural gene acti-
vation, the atherosclerotic vascular process and increase
survival, and gene-activating xenobiotics upregulate
mechanisms that produce lipoprotein pattern typical of
very old people together with reduced incidence of car-
diovascular, metabolic and other diseases. Avoiding
unhealthy stress and managing it properly promotes
health and increases life expectancy.
The positive effects of living habits and pharmacologi-
cal compounds on the incidence of cardiovascular, meta-
bolic and other diseases, and life expectancy, emphasize
the importance of future activities that increase the
adherence to both healthy lifestyle and drug treatment,
and further of searching of new, effective and well toler-
ated agents and therapies.
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